MacroGenics News
Most Popular MacroGenics Story
Eli Lilly forges $1B diabetes deal
Eli Lilly is putting down a $41 million payment to acquire exclusive rights to MacroGenics' diabetes drug teplizumab in a deal that could be worth more than a billion dollars in total. Read more...
Latest Headlines
- September 25, 2008
- July 17, 2008
- May 7, 2008
- October 23, 2007
- October 18, 2007
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
